J&J Pushes New Treatment Paradigm for Invega Sustenna
Executive Summary
Johnson & Johnson is looking at innovative ways to build the value of its just-approved, monthly injectable schizophrenia drug Invega Sustenna, including continuing ongoing outcomes studies and creating appropriate partnerships with payers and others, as part of a broader plan for a "new treatment paradigm" in the treatment of schizophrenia
You may also be interested in...
Opioid Addiction Indication Could Offer Fix For Alkermes' Troubled Vivitrol
Alkermes' four-year-old Vivitrol has been struggling to get its head above water as a therapy for alcoholism. But fast-track status for a new opioid addiction indication and a slew of supportive studies at the American Psychiatric Association meeting offer the $900-a-month injectable a shot at recovery
Opioid Addiction Indication Could Offer Fix For Alkermes' Troubled Vivitrol
Alkermes' four-year-old Vivitrol has been struggling to get its head above water as a therapy for alcoholism. But fast-track status for a new opioid addiction indication and a slew of supportive studies at the American Psychiatric Association meeting offer the $900-a-month injectable a shot at recovery
Alkermes To Put Its Long-Acting Stamp On Trusted Blockbusters, Starting With Abilify
Alkermes unveils patented, monthly injectable form of aripiprazole, developed without Bristol/Otsuka. Up next: Pfizer/Amgen's Enbrel.